Business · 22/03/2024Updated: 10/16/2026 · 1 min read
Prospective Grant of an Exclusive Patent License: Adoptive T Cell Therapy Products Produced Using a Pharmacological p38 Mitogen-Activated Protein Kinase (MAPK) Inhibitor
The National Cancer Institute is considering granting an Exclusive Patent License to Poolbeg Pharma (UK) Limited to practice inventions related to adoptive T cell therapy products.